Background: Information about the impact of cancer treatments on patients' quality of life (QoL) is of paramount importance to patients and treating oncologists. Cancer trials that do not specify QoL as an outcome or fail to report collected QoL data, omit crucial information for decision making. To estimate the magnitude of these problems, we investigated how frequently QoL outcomes were specified in protocols of cancer trials and subsequently reported. †
Design: Retrospective cohort study of RCT protocols approved by six research ethics committees in Switzerland, Germany, and Canada between 2000 and 2003. We compared protocols to corresponding publications, which were identified through literature searches and investigator surveys.
Results: Of the 173 cancer trials, 90 (52%) specified QoL outcomes in their protocol, 2 (1%) as primary and 88 (51%) as secondary outcome. Of the 173 trials, 35 (20%) reported QoL outcomes in a corresponding publication (4 modified from the protocol), 18 (10%) were published but failed to report QoL outcomes in the primary or a secondary publication, and 37 (21%) were not published at all. Of the 83 (48%) trials that did not specify QoL outcomes in their protocol, none subsequently reported QoL outcomes. Failure to report pre-specified QoL outcomes was not associated with industry sponsorship (versus non-industry), sample size, and multicentre (versus single centre) status but possibly with trial discontinuation.
Conclusions: About half of cancer trials specified QoL outcomes in their protocols. However, only 20% reported any QoL data in associated publications. Highly relevant information for decision making is often unavailable to patients, oncologists, and health policymakers. Key words: neoplasms, quality of life, publication bias, cohort studies, ethics committees, randomized controlled trials as topic introduction Information about the impact of cancer treatments on patients' quality of life (QoL) is of paramount importance to patients and treating oncologists. Lack of QoL outcomes complicates decision making, especially in palliative situations when the expected survival benefit of a specific therapy may be small but its impact on QoL essential. Therefore, major funding and regulatory agencies, policymakers, and patient organizations increasingly demand measurement of QoL outcomes in clinical studies [1, 2] .
In spite of the availability of valid instruments such as the European Organization of Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) or the Functional Assessment of Cancer Therapy (FACT) [3, 4] , publications of randomized clinical trials (RCTs) involving cancer patients often do not report on QoL outcomes. For instance, only 41% of advanced-stage lung cancer trials published between 2006 and 2008 reported a QoL outcome [5] . Instead, cancer trials typically focus on survival or tumour size as their primary outcome [5] [6] [7] , a trend that has constantly increased over time [6, 7] . In addition, reporting quality of QoL outcomes was found to be highly variable [8, 9] , and recent initiatives have provided guidance in an effort to improve and harmonize reporting practices [10, 11] .
However, the magnitude of two other fundamental problems, the non-specification of QoL as an outcome and failure to report collected QoL data, is unknown. If cancer trials do not specify QoL as an outcome or fail to report collected QoL data, crucial information is not available for decision making and the risk of misguidance due to selective reporting increases.
The objective of this study was to systematically compare the planning of QoL outcomes in RCT protocols involving cancer patients with subsequent reporting in publications. In addition, we explored risk factors for non-reporting of planned QoL outcomes.
methods study design
This is an ancillary analysis of a large retrospective cohort of RCTs that were approved by six research ethics committees (RECs) in Switzerland (Basel, Lausanne, Zurich, and Lucerne), Germany (Freiburg), and Canada (Hamilton) between 2000 and 2003 [12] [13] [14] [15] . All RECs but one are responsible for human research in large university centres and additional hospitals in their respective catchment areas; one (Lucerne) covers an academic teaching hospital. As a convenience sample, we approached them through existing contacts.
In the present study, we included RCT protocols that involved patients with solid or haematological malignancies. We excluded protocols of RCTs that: (i) compared only different doses or routes of administration of the same drug (early dose-finding studies), (ii) were never started, or (iii) were still on-going as of February 2014. We included full peer-reviewed journal publications of corresponding RCT protocols and excluded research letters, letters to the editor, or conference abstracts.
We conducted comprehensive searches of electronic databases to locate any associated publications. In addition, we hand-searched the files of RECs, and the RECs sent survey questionnaires to study investigators in case of missing information. Our search strategy is reported elsewhere [12] . Two investigators (BK and SS) searched independently and in duplicate for secondary publications reporting additional QoL results. The last update of the search was carried out in February 2014.
definitions
We accepted at face value all QoL outcomes reported as such by investigators of individual trials. We included QoL outcomes irrespective of whether they were measured by multidimensional questionnaires (e.g. EORTC QLQ-C30) or by direct valuation (e.g. visual analogue scale) and whether they were generic or disease specific.
We assessed RCT protocols for industry or investigator sponsorship using the following criteria: the protocol clearly named the sponsor, displayed a company or institution logo prominently, mentioned affiliations of protocol authors, included statements about data ownership or publication rights, or included statements about full funding by industry or public funding agencies [12, 13] .
We considered an RCT discontinued if the investigators indicated discontinuation with a reason in their correspondence with the REC, in a journal publication, or in their response to our survey. If we could not elucidate the reason for RCT discontinuation or if poor participant recruitment was mentioned, we used a pre-specified cut-off of <90% of achieved target sample size to classify discontinuation [12, 13] .
data extraction
Investigators trained in research methodology independently extracted data from eligible RCT protocols and from correspondence between the RECs Volume 26 | No. 9 | September 2015 doi:10.1093/annonc/mdv283 |  Annals of Oncology original articles and the local investigators that was documented in the REC files. Thirtynine percent of protocols from cancer RCTs were extracted in duplicate as an initial calibration process to maximize the consistency of data extraction across reviewers; all corresponding publications were extracted in duplicate. Disagreements were resolved by consensus or by third-party adjudication. Specifically for this project, two oncologists (KC and BK) independently assessed the pairs of protocols and corresponding publications for agreement with respect to the type of QoL instrument(s). For each RCT, they judged independently whether the QoL results were: (i) reported for all subdomains of all specified instruments, (ii) reported but not for all subdomains or instruments, (iii) reported but using completely different instruments than specified, or (iv) not reported at all. In addition, the same two oncologists independently judged the aim of therapy (i.e. palliative, curative, mix, treating side-effects of cancer therapy, unclear) and stage of malignancy (i.e. metastatic, advanced, localized, mix, unclear). They resolved disagreements by consensus or by third-party adjudication.
statistical analysis
For binary data, we summarized results as frequencies and proportions and for continuous data as medians and interquartile ranges (IQRs). We present the results as proportions and associated 95% confidence intervals (95% CIs) using the Jeffreys method [16] . We used the χ 2 test to explore differences in proportions. Using complete case multivariable logistic regression, we tested the association between the dependent variable 'reporting of any QoL outcomes' and the following four independent variables: (i) discontinued RCT (versus completed); (ii) investigator sponsorship (versus industry); (iii) single-centre status (versus multicentre); and (iv) sample size (continuous, in increments of 100). These variables are known to be associated with non-publication of RCTs [13] , and industry sponsorship is known to be associated with selective outcome reporting [17] . Therefore, we hypothesized that these variables might also be associated with failure to report pre-specified QoL outcomes. We limited our regression model to the subset of trials that pre-specified a QoL outcome in their protocol. We carried out sensitivity analyses using (i) the alternative outcome definition 'reporting of QoL outcomes as pre-specified in protocol' and the same independent variables and (ii) multiple imputations for missing information about trial discontinuation (missing in seven RCTs) [18] . We expressed associations as odds ratios (ORs) with 95% CIs and considered two-sided P ≤ 0.05 as significant. We used R version 3.1.0 (www.r-project.org) for all analyses.
results protocol and publication characteristics
Of 894 RCT involving patients, 173 (19%) enrolled patients with cancer ( Figure 1 ). Most cancer trials were multicentre RCTs investigating palliative drug treatments in patients with solid malignancies, half of the trials were industry-sponsored (87, 50%), and one-third were discontinued (50, 34%). The most frequent reason for discontinuation was poor recruitment (22, 13%) ( Table 1) .
Of the 173 cancer trials, 108 (62%) were subsequently published as full journal article; 52 (30%) cancer RCTs were not published at all, and 13 (8%) were published but not as full journal articles. Publication dates ranged between 2003 and 2013, with a median at 2007. The median time between ethical approval and first full journal publication was 5.7 years (IQR, 4.5-7.8 years, range 0.7-12.1 years).
planning of QoL outcomes
The most frequently specified primary outcomes were survival and tumour response ( 45% to 59%) cancer trial protocols reported the measurement of QoL outcomes. QoL was defined as the sole primary outcome in one protocol, as a co-primary outcome in a second, and as a secondary outcome in 88 protocols. The remaining 83 (48%, 95% CI 41% to 55%) RCTs failed to specify a QoL outcome in their protocol (and none of these reported a QoL outcome in subsequent publications). The proportion of RCT specifying QoL outcomes did not differ significantly across RECs (supplementary Table 1 , available at Annals of Oncology online).
Most RCT protocols (57, 63%) specified one QoL instrument; the remaining specified two (26%) or three instruments (3%), or the number of instruments was unclear (8%). The most common QoL instruments to be used were the EORTC QLQ (core questionnaire or modules) in 47 of 90 RCTs (52%), the FACT (core questionnaire or modules) in 19 RCTs (21%), and the EuroQoL-5D (EQ-5D) in 5 RCTS (6%). Other instruments were used in 9 RCTs (10%), and instruments were not specified in 15 (17%). The frequency of planning of QoL outcomes did not differ significantly between investigator-sponsored (47/86, 55%) and industry-sponsored (43/87, 49%) RCTs (P = 0.49). Of 112 RCT protocols that investigated palliative treatments, 65 (57%) planned to measure QoL.
reporting of QoL outcomes
Of the 173 cancer RCTs, 35 (20%, 95% CI 15% to 27%) reported QoL outcomes in a corresponding publication (including 6 secondary publications); of these, 31 (18%, 95% CI 13% to 24%) reported QoL outcomes exactly as specified and 4 (2%, 95% CI 1% to 5%) modified reporting from the protocol (3 reported only one of two specified instruments; 1 reported two completely different instruments, none reported subscales only). Of the 173 trials, 37 (21%, 95% CI 16% to 28%) specified QoL outcomes in the protocol but remained unpublished after a median follow-up of 11.6 years (range, 8.8-12.6 years), and 18 (10%, 95% CI 7% to 16%) specified QoL outcomes but failed to report any QoL outcomes in subsequent publications ( Table 2 ).
risk factors for non-reporting of QoL outcomes
Using complete cases only, none of the independent factors we explored (investigator sponsorship, sample size, trial discontinuation, or single-centre status) was significantly associated with failure to report any QoL outcomes (Table 3) . This finding was confirmed in a sensitivity analysis with the alternative outcome 'failure to report QoL outcomes exactly as specified in protocol' (supplementary Table 2 , available at Annals of Oncology online). When we used multiple imputations, trial discontinuation was significantly associated with failure to report any QoL outcome (OR 2.88, 95% CI 1.00-8.29) and failure to report QoL outcomes exactly as specified in protocol (OR 3.20, 95% CI 1.07-9.64) (supplementary Tables 3 and 4 , available at Annals of Oncology online).
discussion main findings
Approximately half of cancer RCTs specified QoL outcomes in their protocols; however, only 20% reported any QoL data in associated publications. The main reason for the failure to report QoL outcomes was non-specification in the protocol (48%), followed by non-publication of the trial (21%), and non-reporting of QoL outcomes reported in protocols in subsequent publications (10%). In other words, if QoL outcomes were specified at all, most of them were not reported. Failure to report pre-specified QoL outcomes was possibly associated with trial discontinuation but not with sponsorship, sample size, or single-centre status.
strength and limitations
The data for the present study were collected as part of a large international cohort involving six RECs that allowed us full access to RCT protocols and filed correspondence [12, 13] . As outlined previously [19, 20] . Comparing protocols with subsequent publications is the most reliable method to evaluate the reporting of RCTs. We identified corresponding publications by systematically searching REC files, multiple electronic databases, and by contacting trialists through the REC in charge [12] . We focused on protocols that had been approved 10 or more years after REC approval to minimize the number of on-going or unpublished RCTs [13] . We involved only trained methodologists in data abstraction and two oncologists who independently categorized the patient populations regarding the intention of treatment.
Our study has limitations. Because we extracted a total of 1017 RCT protocols and corresponding publications for the main project [13] , we used single data extraction for 61% of cancer trial protocols due to limited resources, thereby potentially introducing extraction errors. However, we used pre-piloted extraction forms with detailed written instructions, conducted formal calibration exercises with all data extractors, and measured agreement between independent data extractors from a random sample of protocols at several points during the process. Agreement was good with no more than two discrepancies in 30 extracted key variables [13] . We used a convenience sample of six RECs in three countries. We cannot claim that these are representative for other RECs in these or other countries; however, to our knowledge, they are not in any way idiosyncratic.
We implicitly assumed that collection of QoL outcomes would have been important in all included cancer trials. Most trials from our sample included patients who were treated with a palliative intention; evaluating the impact of experimental treatments on QoL is more than appropriate in these settings. In addition, we excluded dose-finding studies that typically do not include QoL as an outcome. However, we acknowledge that there may be instances where collection of QoL outcomes in cancer patients may be less important, e.g. when treating acute life-threatening conditions (six RCTs) or if the QoL outcomes related to this intervention have been previously well described (which is rather unlikely). We decided a priori to include any QoL instrument at face value, which is irrespective of its validity in a specific setting. We felt that further sub-division into validated, non-validated, and unclear would add an additional level of complexity but would be unlikely to affect our conclusions.
Finally, we did not ask investigators for unreported study results or the reasons why a study or a pre-specified outcome was not published. Therefore, we could not investigate whether, for example the level of statistical significance influenced the decision to report the outcome in the publication [17] .
comparison with other studies
Our study confirms the previously reported large extent of under-reporting of RCT outcomes [17] . To our knowledge, this is the first study to assess planning of QoL outcomes in RCTs protocols involving cancer patients and the subsequent concordance of reporting.
We can only speculate about the reasons why investigators of oncological studies initially plan to measure QoL but then often do not report QoL outcome data. Earlier studies hypothesized that investigators may encounter methodological difficulties with analysing or interpreting QoL outcomes [21] , or may distrust the integrity of their QoL data due to inconsistent collection or substantial missingness of data [22] . It is unlikely that investigator did not collect any data for the QoL outcomes that they specified in the protocol; a recent survey of RCT investigators suggested that in only 13 of 419 RCTs (3%) investigators did not collect data for pre-specified outcomes [23] .
We assume that the most likely reasons for not reporting of QoL outcomes in cancer RCTs are similar to those that have been repeatedly identified by other studies: data for secondary outcomes were not analysed after negative main results [23] , or findings might be inconclusive or unfavourable [17] . One reason for inconclusive QoL results and subsequent non-publication may include premature trial discontinuation as suggested by our regression analysis. Finally, the failure to report QoL outcomes may also be motivated by reasons such as journal space restrictions, data being perceived as uninteresting, or trialists' lack of awareness of the implications [23, 24] .
Our data did not support the finding of a smaller study (25 cancer RCTs) that cancer RCTs recruit more successfully than other RCTs [25] . About a third of cancer RCTs were prematurely discontinued and 13% because of poor recruitment. These proportions were similar to previously reported findings in RCTs of all disciplines of which 28% were prematurely discontinued and 11% due to poor recruitment [13] .
implications Failure to report pre-specified outcomes can seriously bias published evidence [26] , especially because positive findings are more likely to be reported than negative findings [17] . For instance, a meta-analysis of cancer trials suggested that administration of erythropoiesis-stimulating agents prolonged survival, while an updated individual patient data meta-analysis that included previously unpublished outcome data showed no significant effect [27] .
Given the importance of QoL outcomes for cancer patients and the risk of bias introduced by selective reporting, we believe that the oncology community should take action to address this problem. A number of solutions are possible; one would be that journals request protocols to accompany all manuscript submissions and ensure concordance between planned and reported outcomes.
conclusion Only ∼20% of cancer RCTs approved by RECs subsequently reported QoL outcomes. Most cancer RCTs either never specified QoL outcomes, did so but were never published, or failed to report pre-specified QoL outcomes in their corresponding publications. Consequently, highly relevant information is often 
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